BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38618952)

  • 1. Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis.
    Zhang C; Yu M; Hepperla AJ; Zhang Z; Raj R; Zhong H; Zhou J; Hu L; Fang J; Liu H; Liang Q; Jia L; Liao C; Xi S; Simon JM; Xu K; Liu Z; Nam Y; Kapur P; Zhang Q
    J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VHL governs m6A modification and PIK3R3 mRNA stability in clear cell renal cell carcinomas.
    Lee H; Zhuang L; Gan B
    J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. METTL14-mediated N
    Liu Z; Sun T; Piao C; Zhang Z; Kong C
    Cell Commun Signal; 2022 Mar; 20(1):36. PubMed ID: 35305660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
    Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
    Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
    Petrella BL; Brinckerhoff CE
    Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
    Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
    Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL14-mediated N6-methyladenosine modification of Pten mRNA inhibits tumour progression in clear-cell renal cell carcinoma.
    Zhang L; Luo X; Qiao S
    Br J Cancer; 2022 Jul; 127(1):30-42. PubMed ID: 35249103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
    Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
    Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
    Ma Z; Li Q; Liu P; Dong W; Zuo Y
    Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methyltransferase-like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1.
    Liu T; Wang H; Fu Z; Wang Z; Wang J; Gan X; Wang A; Wang L
    Cancer Sci; 2022 Feb; 113(2):446-458. PubMed ID: 34813676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma.
    Zhu D; Liu Y; Chen J; Wang Q; Li Y; Zhu Y; Feng J; Jiang J
    J Transl Med; 2022 Jul; 20(1):298. PubMed ID: 35794583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.
    Wolf MM; Madden MZ; Arner EN; Bader JE; Ye X; Vlach L; Tigue ML; Landis MD; Jonker PB; Hatem Z; Steiner KK; Gaines DK; Reinfeld BI; Hathaway ES; Xin F; Tantawy MN; Haake SM; Jonasch E; Muir A; Weiss VL; Beckermann KE; Rathmell WK; Rathmell JC
    J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer.
    Xu Y; Song M; Hong Z; Chen W; Zhang Q; Zhou J; Yang C; He Z; Yu J; Peng X; Zhu Q; Li S; Ji K; Liu M; Zuo Q
    J Exp Clin Cancer Res; 2023 Jan; 42(1):10. PubMed ID: 36609396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.
    Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X
    Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Activation of HIF-1α/ACLY signaling axis promotes progression of clear cell renal cell carcinoma with VHL inactivation mutation].
    Ma Y; Wang YH; Huang S; Zou ZG; Hu L; Guo LC
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1230-1236. PubMed ID: 38058039
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The m
    Xiao Y; Thakkar KN; Zhao H; Broughton J; Li Y; Seoane JA; Diep AN; Metzner TJ; von Eyben R; Dill DL; Brooks JD; Curtis C; Leppert JT; Ye J; Peehl DM; Giaccia AJ; Sinha S; Rankin EB
    Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21441-21449. PubMed ID: 32817424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.